Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: Type I interferon receptor

Latest Information Update: 28 Jan 2005

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono; Weizmann Institute of Science; Yeda
  • Developer Merck Serono; Yeda
  • Class
  • Mechanism of Action Interferon alpha inhibitors; Interferon beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Autoimmune disorders; Multiple sclerosis

Most Recent Events

  • 29 Mar 2004 Discontinued - Phase-I for Autoimmune disorders in Israel (unspecified route)
  • 29 Mar 2004 Discontinued - Phase-II for Multiple sclerosis in Switzerland (unspecified route)
  • 29 Mar 2004 Discontinued - Preclinical for Autoimmune disorders in Switzerland (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top